Related Experiment Video
Updated: Apr 25, 2026
11:53
Purification and Reconstitution of TRPV1 for Spectroscopic Analysis
Published on: July 3, 2018
7.6K
A small molecule restores function to TRPML1 mutant isoforms responsible for mucolipidosis type IV
Cheng-Chang Chen1, Marco Keller2, Martin Hess3
11] Department of Pharmacy-Center for Drug Research and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universität München, Munchen 81377, Germany [2].
Nature Communications
|August 15, 2014
Summary
Small molecules can restore TRPML1 channel function in Mucolipidosis type IV (MLIV) patient cells. This research offers potential therapeutic strategies by rescuing disease-associated abnormalities in this rare lysosomal storage disorder.
Area of Science:
- Molecular Biology
- Genetics
- Cell Biology
Background:
- Mucolipidosis type IV (MLIV) is a severe autosomal recessive lysosomal storage disorder.
- MLIV is characterized by neurodevelopmental abnormalities and neuro-retinal degeneration.
- Mutations in the TRPML1 gene are the primary cause of MLIV.
Purpose of the Study:
- To identify small-molecule activators that can restore TRPML1 mutant channel function.
- To test the efficacy of these activators in MLIV patient fibroblasts.
- To investigate the potential of small molecules in rescuing disease-associated abnormalities.
Main Methods:
- Utilized lead optimization strategies to discover small-molecule activators.
- Employed the whole-lysosome planar patch-clamp technique to assess TRPML1 channel activity.
- Analyzed MLIV patient fibroblasts expressing specific TRPML1 mutations.
Main Results:
- Activation of MLIV mutant TRPML1 by the endogenous ligand PI(3,5)P2 was significantly reduced.
- Synthetic ligands successfully increased the activity of mutant TRPML1 channels.
- Specific mutations (F465L, F408Δ) were identified to affect pH sensitivity and ligand binding.
- Small molecule treatment rescued lysosomal trafficking defects and zinc accumulation in MLIV fibroblasts.
Conclusions:
- Small molecules can effectively restore TRPML1 channel function in cells with specific MLIV mutations.
- Therapeutic strategies targeting TRPML1 channel activity show promise for MLIV treatment.
- Demonstrated the potential of small molecules to rescue disease-associated cellular abnormalities in MLIV.
